MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

Merck (known as MSD outside the US and Canada) has entered into a funding agreement with Blackstone Life Sciences to support ...

The LEGEND trial showed a 62% complete response (CR) rate with the non-viral gene therapy at six months in NMIBC patients who ...

The Healthcare Businesswomen's Association (HBA) successfully convened the second edition of its annual India Leadership Summit (ILS) at The Lalit Hotel, Mumbai. Under the powerful theme "Winning a ...

ONEOK has badly underperformed peers, dropping 28% YTD, but recent operational and valuation challenges appear priced in. See ...

Fintel reports that on November 10, 2025, Barrington Research maintained coverage of Townsquare Media (NYSE:TSQ) with a ...

Merck’s enlicitide decanoate significantly reduced LDL-C in adults with heterozygous familial hypercholesterolemia in phase 3 CORALreef HeFH trial: Rahway, New Jersey Tuesday, N ...

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy ...

Gene anticipates filing a biologics licence application (BLA) for detalimogene voraplasmid to the FDA in H2 2026.

SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (the "Company"), today announced that it has entered into a securities purchase agreement with a single healthcare ...

Some deals announced by Saudi Crown Prince Mohammed bin Salman in May could be finalized during his trip to D.C. to visit ...

Campbellsville man recently won nearly $58,000 playing the Bluegrass Bucks Hot Hit Jackpots Instant Play game, just months ...